This HTML5 document contains 86 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-shhttp://sh.dbpedia.org/resource/
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n17https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n11http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
dbpedia-srhttp://sr.dbpedia.org/resource/
freebasehttp://rdf.freebase.com/ns/
n21http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Bitopertin
rdf:type
yago:CausalAgent100007347 yago:Substance100020090 n11:ChemicalObject wikidata:Q8386 dbo:ChemicalSubstance yago:Agent114778436 owl:Thing yago:WikicatDrugs dbo:Drug yago:PhysicalEntity100001930 yago:Drug103247620 yago:Matter100020827
rdfs:label
Bitopertin
rdfs:comment
Bitopertin (developmental code names RG1678; RO-4917838) is a glycine reuptake inhibitor which was under development by Roche as an adjunct to antipsychotics for the treatment of persistent negative symptoms or suboptimally controlled positive symptoms associated with schizophrenia. Research into this indication has been largely halted as a result of disappointing trial results.
foaf:depiction
n21:Bitopertin.svg
dcterms:subject
dbc:N-benzoylpiperazines dbc:Glycine_reuptake_inhibitors dbc:Experimental_drugs dbc:Organofluorides dbc:Benzosulfones dbc:Trifluoromethyl_compounds
dbo:wikiPageID
36716273
dbo:wikiPageRevisionID
1084694348
dbo:wikiPageWikiLink
dbr:Reuptake dbr:ORG-25935 dbr:NMDA_receptor dbr:Positive_symptoms dbr:Hoffmann-La_Roche dbr:Adjunctive_therapy dbr:Glutamate dbc:N-benzoylpiperazines dbr:Phases_of_clinical_research dbr:Glutamatergic dbr:Neurotransmitter dbr:Glycine_reuptake_inhibitor dbr:Antipsychotic dbr:Synaptic_cleft dbr:Schizophrenia dbr:Glycine_transporter_1 dbc:Experimental_drugs dbr:Glycine dbc:Glycine_reuptake_inhibitors dbr:Co-agonist dbc:Trifluoromethyl_compounds dbc:Organofluorides dbc:Benzosulfones dbr:Negative_symptoms
owl:sameAs
freebase:m.0l8mtwy dbpedia-sh:Bitopertin wikidata:Q4918919 n17:4ZCHA yago-res:Bitopertin dbpedia-sr:Bitopertin
dbp:wikiPageUsesTemplate
dbt:Drugbox dbt:Short_description dbt:Glycine_receptor_modulators dbt:Reflist dbt:Use_dmy_dates
dbo:thumbnail
n21:Bitopertin.svg?width=300
dbp:atcPrefix
none
dbp:c
21
dbp:casNumber
845614
dbp:chembl
1169880
dbp:chemspiderid
25034798
dbp:f
7
dbp:h
20
dbp:iupacName
{4-[3-Fluoro-5-pyridin-2-yl]piperazin-1-yl}{5--2-[-2,2,2-trifluoro-1-methylethoxy]phenyl}methanone
dbp:kegg
D10186
dbp:n
3
dbp:o
4
dbp:s
1
dbp:smiles
CCOc1cccSC
dbp:stdinchi
1
dbp:stdinchikey
YUUGYIUSCYNSQR-LBPRGKRZSA-N
dbp:unii
Q8L6AN59YY
dbp:width
270
dbo:abstract
Bitopertin (developmental code names RG1678; RO-4917838) is a glycine reuptake inhibitor which was under development by Roche as an adjunct to antipsychotics for the treatment of persistent negative symptoms or suboptimally controlled positive symptoms associated with schizophrenia. Research into this indication has been largely halted as a result of disappointing trial results. Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that increases levels of the neurotransmitter glycine by inhibiting its reuptake from the synaptic cleft. Glycine acts as a required co-agonist along with glutamate at N-methyl-D-aspartate (NMDA) receptors. Dysfunction of NMDA receptors may play a key role in the pathogenesis of schizophrenia and modulation of glutamatergic signalling via increased concentrations of glycine in the synaptic cleft may help potentiate NMDA receptor function and improve the symptoms of schizophrenia. In a phase II proof-of-concept study, patients on bitopertin experienced a significant improvement in the change of the Negative Symptom Factor Score from baseline within 8 weeks (from −4.86 in the placebo group to −6.65 in the treatment group, p<0.05, per-protocol population). In addition, 83% of patients on bitopertin described an improvement of negative symptoms on the CGI-I1 versus 66% on placebo (p<0.05, per-protocol population). In January 2014, Roche reported that bitopertin failed to meet its endpoints in two phase III trials assessing its efficacy in reducing negative symptoms of schizophrenia. Subsequently, in April 2014, Roche announced that it was discontinuing all except one of its phase III trials of bitopertin for schizophrenia.
dbp:iupharLigand
7546
gold:hypernym
dbr:Inhibitor
prov:wasDerivedFrom
wikipedia-en:Bitopertin?oldid=1084694348&ns=0
dbo:wikiPageLength
4255
dbo:casNumber
845614-11-1
dbo:chEMBL
1169880
dbo:fdaUniiCode
Q8L6AN59YY
dbo:kegg
D10186
foaf:isPrimaryTopicOf
wikipedia-en:Bitopertin